NCT05954429View on ClinicalTrials.gov

A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

February 28, 2026

Study Completion Date

August 31, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

serplulimab

"Serplulimab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc.~300 mg, q3w Other name: HLX10"

DRUG

Fruquintinib

5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.

Trial Locations (1)

200000

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Junjie Peng

OTHER

NCT05954429 - A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | Biotech Hunter | Biotech Hunter